0QNA logo

Basilea Pharmaceutica LSE:0QNA Stock Report

Last Price

CHF37.65

Market Cap

CHF451.9m

7D

5.2%

1Y

-25.2%

Updated

29 Mar, 2024

Data

Company Financials +

Basilea Pharmaceutica AG

LSE:0QNA Stock Report

Market Cap: CHF451.9m

0QNA Stock Overview

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.

0QNA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance2/6
Financial Health0/6
Dividends0/6

Basilea Pharmaceutica AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Basilea Pharmaceutica
Historical stock prices
Current Share PriceCHF37.65
52 Week HighCHF50.60
52 Week LowCHF32.20
Beta0.56
1 Month Change4.67%
3 Month Change5.02%
1 Year Change-25.19%
3 Year Change-20.50%
5 Year Change-20.13%
Change since IPO-68.23%

Recent News & Updates

Recent updates

Shareholder Returns

0QNAGB BiotechsGB Market
7D5.2%-1.6%0.9%
1Y-25.2%-28.9%2.2%

Return vs Industry: 0QNA exceeded the UK Biotechs industry which returned -27.3% over the past year.

Return vs Market: 0QNA underperformed the UK Market which returned 2.7% over the past year.

Price Volatility

Is 0QNA's price volatile compared to industry and market?
0QNA volatility
0QNA Average Weekly Movement5.4%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.1%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QNA has not had significant price volatility in the past 3 months.

Volatility Over Time: 0QNA's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000147David Veitchhttps://www.basilea.com

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.

Basilea Pharmaceutica AG Fundamentals Summary

How do Basilea Pharmaceutica's earnings and revenue compare to its market cap?
0QNA fundamental statistics
Market capCHF451.92m
Earnings (TTM)CHF10.45m
Revenue (TTM)CHF157.63m

43.2x

P/E Ratio

2.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QNA income statement (TTM)
RevenueCHF157.63m
Cost of RevenueCHF104.65m
Gross ProfitCHF52.99m
Other ExpensesCHF42.54m
EarningsCHF10.45m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Aug 13, 2024

Earnings per share (EPS)0.87
Gross Margin33.61%
Net Profit Margin6.63%
Debt/Equity Ratio-1,108.7%

How did 0QNA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.